CRDL · NASDAQ

Cardiol Therapeutics Inc.

Q: How do I get CRDL news from the API?

Call GET /v1/news?tickers=CRDL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

$1.07 +0.03 (+2.39%)

Company overview

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease. Its lead product is CardiolRx, which is in a Phase II/III multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate its efficacy and safety in acute myocarditis. The company is also developing a subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related to the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Market cap: $129M
Employees: 18
Headquarters: Oakville, ON
Website: cardiolrx.com
CEO: David G. Elsley
Listed: January 15, 2019
P/E: -2.73
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: -$52,730
Operating income: -$35.6M
EBITDA: -$35.3M
Net income: -$36.4M
EPS: -$0.39
Total assets: $31.5M
Total debt: $116,707
Earnings yield: -36.59%

Price chart

CRDL 1D NASDAQ O1.11H1.12L1.03C1.04-0.07 (-6.31%)Vol740.37K

News

Ticker	Type	Headline	Source	Published
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and .…	PR Newswire	Nov 3, 5:03:00 PM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy	PR Newswire	Sep 23, 6:00:00 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds	PR Newswire	Sep 16, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Stock news	5 Small Drug Stocks Poised to Benefit From a Biotech Recovery	Zacks Investment Research	Sep 14, 10:30:59 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission	PR Newswire	Sep 10, 5:00:00 PM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference	PRNewsWire	Sep 9, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Stock news	Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?	Zacks Investment Research	Aug 25, 10:41:12 AM ET
CRDLCardiol Therapeutics Inc.	Stock news	Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?	Zacks Investment Research	Aug 24, 1:01:10 PM ET
CRDLCardiol Therapeutics Inc.	Stock news	Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial	MarketBeat	Aug 12, 8:02:20 AM ET
CRDLCardiol Therapeutics Inc.	Stock news	Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday	Defense World	Aug 6, 3:11:15 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference	PRNewsWire	Aug 5, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PRNewsWire	Jul 14, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	PRNewsWire	Jul 9, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	PRNewsWire	May 14, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association	PRNewsWire	May 7, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program	PRNewsWire	Apr 28, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Stock news	Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)	Defense World	Apr 24, 2:31:15 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart	Newsfile Corp	Apr 14, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Press release	Cardiol Therapeutics Announces Year-End 2025 Update on Operations	Newsfile Corp	Apr 1, 7:27:00 AM ET
CRDLCardiol Therapeutics Inc.	Stock news	Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference	Defense World	Mar 10, 2:02:49 AM ET

FAQ

Questions about Cardiol Therapeutics Inc.

What does Cardiol Therapeutics Inc. do?

What is CRDL's market cap?

Cardiol Therapeutics Inc. (CRDL) is a listed stock with a live quote. The latest market cap on this page is $129M.

Where is Cardiol Therapeutics Inc. headquartered?

Cardiol Therapeutics Inc. is headquartered in Oakville, ON.

How do I get CRDL news from the API?

Call GET /v1/news?tickers=CRDL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does CRDL news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CRDL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the CRDL price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs